Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’
Growth For Teriparatide Biosimilar Terrosa Expected To Slow In 2022
Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.
You may also be interested in...
Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.
Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.
Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.